KYMR · Kymera Therapeutics, Inc.
$110.57
-3.53% last session
End-of-day data · updated 2026-07-28
Market cap
$9B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
-25.3
Dividend yield
—
Beta
1.96
Avg volume
1M
Employees
0K
2D change
—
5D change
-0.30%
10D change
-4.94%
30D change
1.79%
60D change
35.16%
MTD change
-3.63%
YTD change
41.43%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KYMR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
RBC Capital
Sector Perform$115
+4.0% vs priceBank of America
Buy$125
+13.1% vs priceUBS
Buy$128
+15.8% vs priceCitigroup
Buy$120
+8.5% vs priceBarclays
Overweight$133
+20.3% vs priceJP Morgan
Overweight$125
+13.1% vs priceJefferies
Buy$122
+10.3% vs priceWells Fargo
Overweight$116
+4.9% vs priceMorgan Stanley
Overweight$127
+14.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | Guggenheim | Maintains | Buy | $125 → $135 |
| 2026-07-16 | Mizuho | Maintains | Outperform | $120 → $140 |
| 2026-07-13 | RBC Capital | Downgrade | Outperform → Sector Perform | $106 → $115 |
| 2026-06-30 | Bank of America | Maintains | Buy | $110 → $125 |
| 2026-06-29 | Truist Securities | Maintains | Buy | $116 → $136 |
| 2026-06-29 | B. Riley Securities | Maintains | Buy | $117 → $155 |
| 2026-06-26 | Canaccord Genuity | Maintains | Buy | $106 → $129 |
| 2026-06-25 | BTIG | Reiterates | Buy | $134 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 10.6% above the 50-day MA ($96.03).
- Price vs 200-day MA: Trading 30.8% above the 200-day MA ($81.19).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.97) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($37.68) and high ($119.35).
KYMR Price Chart
Loading chart for KYMR…
Fundamentals
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.